136 related articles for article (PubMed ID: 33141042)
1. T851I mutation of human large tumor suppressor 1 disrupts its kinase activity and tumor-suppressor functions.
Zhang Q; Du X; He Q; Shi W; Mei L; Qv M; Tan D; Wu J; Zeng LH; Wu X
Life Sci; 2021 Jan; 264():118655. PubMed ID: 33141042
[TBL] [Abstract][Full Text] [Related]
2. SUMOylation of large tumor suppressor 1 at Lys751 attenuates its kinase activity and tumor-suppressor functions.
Mei L; Yuan L; Shi W; Fan S; Tang C; Fan X; Yang W; Qian Y; Hussain M; Wu X
Cancer Lett; 2017 Feb; 386():1-11. PubMed ID: 27847303
[TBL] [Abstract][Full Text] [Related]
3. WWC proteins mediate LATS1/2 activation by Hippo kinases and imply a tumor suppression strategy.
Qi S; Zhu Y; Liu X; Li P; Wang Y; Zeng Y; Yu A; Wang Y; Sha Z; Zhong Z; Zhu R; Yuan H; Ye D; Huang S; Ling C; Xu Y; Zhou D; Zhang L; Yu FX
Mol Cell; 2022 May; 82(10):1850-1864.e7. PubMed ID: 35429439
[TBL] [Abstract][Full Text] [Related]
4. Src Inhibits the Hippo Tumor Suppressor Pathway through Tyrosine Phosphorylation of Lats1.
Si Y; Ji X; Cao X; Dai X; Xu L; Zhao H; Guo X; Yan H; Zhang H; Zhu C; Zhou Q; Tang M; Xia Z; Li L; Cong YS; Ye S; Liang T; Feng XH; Zhao B
Cancer Res; 2017 Sep; 77(18):4868-4880. PubMed ID: 28754671
[TBL] [Abstract][Full Text] [Related]
5. MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway.
Meng Z; Moroishi T; Mottier-Pavie V; Plouffe SW; Hansen CG; Hong AW; Park HW; Mo JS; Lu W; Lu S; Flores F; Yu FX; Halder G; Guan KL
Nat Commun; 2015 Oct; 6():8357. PubMed ID: 26437443
[TBL] [Abstract][Full Text] [Related]
6. Lipid kinase PIP5Kα contributes to Hippo pathway activation via interaction with Merlin and by mediating plasma membrane targeting of LATS1.
Le TPH; Nguyen NTT; Le DDT; Anwar MA; Lee SY
Cell Commun Signal; 2023 Jun; 21(1):149. PubMed ID: 37337213
[TBL] [Abstract][Full Text] [Related]
7. Angiomotins stimulate LATS kinase autophosphorylation and act as scaffolds that promote Hippo signaling.
Mana-Capelli S; McCollum D
J Biol Chem; 2018 Nov; 293(47):18230-18241. PubMed ID: 30266805
[TBL] [Abstract][Full Text] [Related]
8. LATS1 K751 acetylation blocks activation of Hippo signalling and switches LATS1 from a tumor suppressor to an oncoprotein.
Yang S; Xu W; Liu C; Jin J; Li X; Jiang Y; Zhang L; Meng X; Zhan J; Zhang H
Sci China Life Sci; 2022 Jan; 65(1):129-141. PubMed ID: 33945069
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
10. Cell type-dependent function of LATS1/2 in cancer cell growth.
Pan WW; Moroishi T; Koo JH; Guan KL
Oncogene; 2019 Apr; 38(14):2595-2610. PubMed ID: 30531839
[TBL] [Abstract][Full Text] [Related]
11. Calmodulin activates the Hippo signaling pathway by promoting LATS1 kinase-mediated inhibitory phosphorylation of the transcriptional coactivator YAP.
Thines L; Gorisse L; Li Z; Sayedyahossein S; Sacks DB
J Biol Chem; 2022 May; 298(5):101839. PubMed ID: 35307353
[TBL] [Abstract][Full Text] [Related]
12. Deubiquitylase USP9X suppresses tumorigenesis by stabilizing large tumor suppressor kinase 2 (LATS2) in the Hippo pathway.
Zhu C; Ji X; Zhang H; Zhou Q; Cao X; Tang M; Si Y; Yan H; Li L; Liang T; Feng XH; Zhao B
J Biol Chem; 2018 Jan; 293(4):1178-1191. PubMed ID: 29183995
[TBL] [Abstract][Full Text] [Related]
13. Hippo-Yap Signaling Maintains Sinoatrial Node Homeostasis.
Zheng M; Li RG; Song J; Zhao X; Tang L; Erhardt S; Chen W; Nguyen BH; Li X; Li M; Wang J; Evans SM; Christoffels VM; Li N; Wang J
Circulation; 2022 Nov; 146(22):1694-1711. PubMed ID: 36317529
[TBL] [Abstract][Full Text] [Related]
14. The N6-methyladenosine METTL3 regulates tumorigenesis and glycolysis by mediating m6A methylation of the tumor suppressor LATS1 in breast cancer.
Xu Y; Song M; Hong Z; Chen W; Zhang Q; Zhou J; Yang C; He Z; Yu J; Peng X; Zhu Q; Li S; Ji K; Liu M; Zuo Q
J Exp Clin Cancer Res; 2023 Jan; 42(1):10. PubMed ID: 36609396
[TBL] [Abstract][Full Text] [Related]
15. Tumor suppressor LATS1 is a negative regulator of oncogene YAP.
Hao Y; Chun A; Cheung K; Rashidi B; Yang X
J Biol Chem; 2008 Feb; 283(9):5496-509. PubMed ID: 18158288
[TBL] [Abstract][Full Text] [Related]
16. Large tumor suppressor homologs 1 and 2 regulate mouse liver progenitor cell proliferation and maturation through antagonism of the coactivators YAP and TAZ.
Yi J; Lu L; Yanger K; Wang W; Sohn BH; Stanger BZ; Zhang M; Martin JF; Ajani JA; Chen J; Lee JS; Song S; Johnson RL
Hepatology; 2016 Nov; 64(5):1757-1772. PubMed ID: 27531557
[TBL] [Abstract][Full Text] [Related]
17. A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis.
Moroishi T; Park HW; Qin B; Chen Q; Meng Z; Plouffe SW; Taniguchi K; Yu FX; Karin M; Pan D; Guan KL
Genes Dev; 2015 Jun; 29(12):1271-84. PubMed ID: 26109050
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of angiomotin by Lats1/2 kinases inhibits F-actin binding, cell migration, and angiogenesis.
Dai X; She P; Chi F; Feng Y; Liu H; Jin D; Zhao Y; Guo X; Jiang D; Guan KL; Zhong TP; Zhao B
J Biol Chem; 2013 Nov; 288(47):34041-34051. PubMed ID: 24106267
[TBL] [Abstract][Full Text] [Related]
19. Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway.
Huntoon CJ; Nye MD; Geng L; Peterson KL; Flatten KS; Haluska P; Kaufmann SH; Karnitz LM
Cancer Res; 2010 Nov; 70(21):8642-50. PubMed ID: 20841485
[TBL] [Abstract][Full Text] [Related]
20. Liquid-Liquid Phase Separation of DDR1 Counteracts the Hippo Pathway to Orchestrate Arterial Stiffening.
Liu J; Wang J; Liu Y; Xie SA; Zhang J; Zhao C; Zhou Y; Pang W; Yao W; Peng Q; Wang X; Zhou J
Circ Res; 2023 Jan; 132(1):87-105. PubMed ID: 36475898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
